首页 > 最新文献

Ceska a Slovenska Farmacie最新文献

英文 中文
Hyperferritinemia as a factor associated with poor prognosis in COVID-19 patients. 高铁蛋白血症是 COVID-19 患者预后不良的一个相关因素。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Nuhad Mohammed Al-Dulaimi, Mahmood Jassim Mohammed, Saad T Mutlk, Khalid F Al-Rawi, Hameed Hussein Ali, Bilal J M Aldahham, Faisal Al-Ani, Osamah Al-Ani, Yaqout A Hamed, Aus T Ali

Worldwide, hundreds of millions of people have been infected with COVID-19 since December 2019; however, about 20% or less developed severe symptoms. The main aim of the current study was to  assess  the  relationship  between  the  severity of Covid-19 and different clinical and laboratory parameters. A total number of 466 Arabs have willingly joined this prospective cohort. Out of the total number, 297 subjects (63.7%) had negative COVID-19 tests, and thus, they were recruited as controls, while 169 subjects (36.3%) who tested positive for COVID-19 were enrolled as cases. Out of the total number of COVID-19 patients, 127 (75.15%) presented with mild symptoms, and 42 (24.85%) had severe symptoms. The age range for the participants was 20 to 82 years. Compared with controls, the severity of the disease was associated with significantly high ferritin levels (P < 0.001). The severity of the disease was also associated with a significant increase in C-reactive protein (P < 0.001), D-dimer (P < 0.001), white blood cell count (WBC) (P < 0.01), IgM (P < 0.001), and Granulocytes (P < 0.01). In addition, severe COVID-19 symptoms in the current study were associated with a significant decrease in lymphocytes (P < 0.01). There was a four-fold increase in serum ferritin levels in COVID-19 patients presented with severe symptoms upon admission. The former was associated with significantly high levels of CRP and D-dimer. Thus, hyperferritinemia, together with high CRP and D-dimer concentrations, may serve as reliable predictors for disease severity and poor prognosis in Arabs with COVID-19.

自2019年12月以来,全球已有数亿人感染了COVID-19,但约20%或更少出现严重症状。本次研究的主要目的是评估Covid-19严重程度与不同临床和实验室参数之间的关系。共有 466 名阿拉伯人自愿加入了这项前瞻性队列研究。其中,297 名受试者(63.7%)的 COVID-19 检测结果为阴性,因此被列为对照组;169 名受试者(36.3%)的 COVID-19 检测结果为阳性,因此被列为病例组。在所有 COVID-19 患者中,127 人(75.15%)症状轻微,42 人(24.85%)症状严重。患者年龄介于 20 岁至 82 岁之间。与对照组相比,病情严重程度与铁蛋白水平明显偏高有关(P < 0.001)。病情严重程度还与 C 反应蛋白(P < 0.001)、D-二聚体(P < 0.001)、白细胞计数(WBC)(P < 0.01)、IgM(P < 0.001)和粒细胞(P < 0.01)的显著增加有关。此外,在本次研究中,严重的 COVID-19 症状与淋巴细胞的显著减少有关(P < 0.01)。入院时出现严重症状的 COVID-19 患者的血清铁蛋白水平增加了四倍。前者与 CRP 和 D-二聚体水平明显升高有关。因此,高铁蛋白血症以及高 CRP 和 D-二聚体浓度可作为 COVID-19 阿拉伯人病情严重程度和预后不良的可靠预测指标。
{"title":"Hyperferritinemia as a factor associated with poor prognosis in COVID-19 patients.","authors":"Nuhad Mohammed Al-Dulaimi, Mahmood Jassim Mohammed, Saad T Mutlk, Khalid F Al-Rawi, Hameed Hussein Ali, Bilal J M Aldahham, Faisal Al-Ani, Osamah Al-Ani, Yaqout A Hamed, Aus T Ali","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Worldwide, hundreds of millions of people have been infected with COVID-19 since December 2019; however, about 20% or less developed severe symptoms. The main aim of the current study was to  assess  the  relationship  between  the  severity of Covid-19 and different clinical and laboratory parameters. A total number of 466 Arabs have willingly joined this prospective cohort. Out of the total number, 297 subjects (63.7%) had negative COVID-19 tests, and thus, they were recruited as controls, while 169 subjects (36.3%) who tested positive for COVID-19 were enrolled as cases. Out of the total number of COVID-19 patients, 127 (75.15%) presented with mild symptoms, and 42 (24.85%) had severe symptoms. The age range for the participants was 20 to 82 years. Compared with controls, the severity of the disease was associated with significantly high ferritin levels (P &lt; 0.001). The severity of the disease was also associated with a significant increase in C-reactive protein (P &lt; 0.001), D-dimer (P &lt; 0.001), white blood cell count (WBC) (P &lt; 0.01), IgM (P &lt; 0.001), and Granulocytes (P &lt; 0.01). In addition, severe COVID-19 symptoms in the current study were associated with a significant decrease in lymphocytes (P &lt; 0.01). There was a four-fold increase in serum ferritin levels in COVID-19 patients presented with severe symptoms upon admission. The former was associated with significantly high levels of CRP and D-dimer. Thus, hyperferritinemia, together with high CRP and D-dimer concentrations, may serve as reliable predictors for disease severity and poor prognosis in Arabs with COVID-19.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 5","pages":"223-232"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colour and content of some metals in honey. 蜂蜜中某些金属的颜色和含量。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Jan Šubert, Jozef Kolář, Jozef Čižmárik

The paper highlights the correlations between the results of instrumental colour measurement and the content of certain metals in kinds of honey. Sufficiently close correlations may lead to the development of procedures for the rapid determination of the content of these metals in honey by colour measurement without the need for more demanding sample preparation.

本文强调了仪器测色结果与蜂蜜中某些金属含量之间的相关性。足够密切的相关性可能导致开发通过颜色测量快速测定蜂蜜中这些金属含量的程序,而不需要更高要求的样品制备。
{"title":"Colour and content of some metals in honey.","authors":"Jan Šubert,&nbsp;Jozef Kolář,&nbsp;Jozef Čižmárik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The paper highlights the correlations between the results of instrumental colour measurement and the content of certain metals in kinds of honey. Sufficiently close correlations may lead to the development of procedures for the rapid determination of the content of these metals in honey by colour measurement without the need for more demanding sample preparation.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 2","pages":"59-62"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Friedrich Jakub Fuker and his universal preventive tincture. 弗里德里希·雅克布·福克和他的通用预防药剂。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
František Šimon

Fridrich Jakub Fuker (1749-1805), a physician from Košice, is the author of works on medical topics, as well as works on social life. In addition to his medical practice, he also owned a pharmacy, and his short work on a universal preventive tincture is related to this. The author argues that there is no universal medicine, but it is possible to prepare a universal preventive preparation suitable for everyone, every age and sex. Fuker has announced that he will prepare such a tincture, available in his pharmacy, along with information on its use. However, he did not divulge its composition, as supposedly, any physician knowledgeable in the matter would figure it out on his own. With the universal tincture, Fuker abandoned rational medicine, perhaps suffering from involutional depression or acting as a salesman.

弗里德里希·雅克布·福克(1749-1805),来自Košice的医生,著有医学方面的著作,也有社会生活方面的著作。除了行医之外,他还拥有一家药房,他在通用预防酊剂方面的短暂工作与此有关。作者认为,没有普遍的药物,但有可能准备一种适用于每个人、每个年龄和性别的普遍预防制剂。福克宣布,他将准备一种酊剂,在他的药房里有售,并提供了使用方法的信息。然而,他没有透露它的成分,因为据推测,任何熟悉这方面的医生都会自己弄清楚。有了通用的酊剂,福克放弃了理性的医学,也许是患上了更年期抑郁症,或者是当了推销员。
{"title":"Friedrich Jakub Fuker and his universal preventive tincture.","authors":"František Šimon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Fridrich Jakub Fuker (1749-1805), a physician from Košice, is the author of works on medical topics, as well as works on social life. In addition to his medical practice, he also owned a pharmacy, and his short work on a universal preventive tincture is related to this. The author argues that there is no universal medicine, but it is possible to prepare a universal preventive preparation suitable for everyone, every age and sex. Fuker has announced that he will prepare such a tincture, available in his pharmacy, along with information on its use. However, he did not divulge its composition, as supposedly, any physician knowledgeable in the matter would figure it out on his own. With the universal tincture, Fuker abandoned rational medicine, perhaps suffering from involutional depression or acting as a salesman.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 3","pages":"141-144"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New trends in advanced parkinson disease stage therapy. 晚期帕金森病分期治疗的新趋势。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Mária Kolesárová, Ondrej Franko, Dalibor Kolesár, Andrea Gažová, Ján Kyselovič

The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing "off" periods in patients has also been noted. In the case of Duodopa and DBS, the "off" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.

该研究的目的是指出新的侵入性治疗方法在治疗晚期帕金森病(PD)方面的贡献,并与经典的口服药物治疗进行比较。数据来自一组43例PD患者,其中39%(17例)采用经典治疗,23%(10例)采用左旋甲酯肠凝胶治疗,19%(8例)采用阿波啡(APO)皮下给药,同样数量的患者采用脑深部刺激(DBS)治疗。根据Hoehn and Yahr分级标准(Hoehn and Yahr, 1967),大多数患者为PD晚期,即4期。研究发现,采用新的治疗方法后,大多数患者的病情有所改善。对口服治疗的需求减少也产生了积极的影响,所有新疗法的需求都显著减少。在每个病人服用抗帕金森药物的数量上观察到益处,我们观察到所有新疗法的减少。新的治疗方法在减少患者“关闭”期的积极作用也被注意到。在多巴和DBS的情况下,“关闭”期缩短了50%,在阿波啡泵中缩短了40%。患者还报告了一些症状的减轻,如强直、震颤和运动迟缓,而运动障碍仍然是一个挑战。根据所获得的结果,可以得出结论,PCh的新治疗方法将有可能控制疾病晚期的典型症状,如果没有这些治疗方法,将导致残疾,这是其适应症的主要原因。然而,在早期阶段,反应良好的患者或进展缓慢的疾病,口服抗帕金森药仍然是治疗的黄金标准。这不仅是由于良好的反应,而且还因为这些经典药物配方的价格要便宜得多。在斯洛伐克,只有经过保险公司医生的二次修订后,才能通过医疗保险获得新的治疗方法。
{"title":"New trends in advanced parkinson disease stage therapy.","authors":"Mária Kolesárová,&nbsp;Ondrej Franko,&nbsp;Dalibor Kolesár,&nbsp;Andrea Gažová,&nbsp;Ján Kyselovič","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing \"off\" periods in patients has also been noted. In the case of Duodopa and DBS, the \"off\" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10823792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, characterization, molecular docking studies of new alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H- -1,2,4-triazole-3-thiol. 5-(2-溴-4-氟苯基)-4-乙基-4H--1,2,4-三唑-3-硫醇新烷基衍生物的合成、表征和分子对接研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Roman Shcherbyna, Valerü Kalchenko, Sergii Kulish, Volodymyr Salionov, Liubov Morozova, Natalia Nedorezaniuk, Olha Mazur

The main goal of this article is to present the results of the synthesis of new alkyl derivatives of 5-(2-bromo4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiol and molecular docking studies against COX-1 and COX-2. Previous studies have established a wide range of biological activity of 1,2,4-triazole derivatives. Therefore, it was essential to determine how a new series of 1,2,4-triazole derivatives would provide potential anti-inflammatory activity. To reach the goal, raw alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiols (2a-2i) from 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole3-thiol (1e) were obtained. The structure of the synthesized compounds was confirmed by 1H-NMR elemental analyses. The individuality and purity of compounds were confirmed by the method of liquid chromatography-mass spectrometry. These compounds have a relatively simple synthesis scheme, which gives them an advantage in creating a potential drug, and the appearance of alkyl radicals in the molecule should positively affect pharmacokinetic indicators, stability, selectivity, and bioavailability. An in silico study was conducted for the synthesized compounds, namely molecular docking, in relation to the interaction with COX-1 and COX-2. Based on the selectivity indexes of binding modes observed for the selected compounds (2e, 2g) with active COX-1 centers, it was found that compounds can reliably exhibit their anti-inflammatory effect through the prostaglandin biosynthesis pathway, inhibiting COX-1 instead of COX-2. The effect of hydrophobic interactions of alkyl groups of 1,2,4-triazole derivatives on changes in affinity and selectivity to COX-1 or COX-2 has also been proven. Therefore, derivatives of 1,2,4 are promising candidates for improvement, further study, and future development of new, more powerful antiinflammatory drugs for therapeutic use.

本文的主要目的是介绍5-(2-溴-4-氟苯基)-4-乙基-4H-1,2,4-三唑-3-硫醇的新烷基衍生物的合成结果以及针对COX-1和COX-2的分子对接研究。先前的研究已经确定了1,2,4-三唑衍生物的广泛生物活性。因此,有必要确定一系列新的1,2,4-三唑衍生物如何提供潜在的抗炎活性。为了达到该目标,从5-(2-溴-4-氟苯基)-4-乙基-4H-1,2,4-三唑-3-硫醇(2a-2i)得到5-(2-溴-4-氟苯基(2-ethyl-4H-1)-4-乙基-2,4-三唑-3-巯基(1e)的粗烷基衍生物。通过1H-NMR元素分析证实了合成的化合物的结构。用液相色谱-质谱法对化合物的个性和纯度进行了确证。这些化合物的合成方案相对简单,这使它们在开发潜在药物方面具有优势,分子中烷基的出现应积极影响药代动力学指标、稳定性、选择性和生物利用度。对合成的化合物,即分子对接,与COX-1和COX-2的相互作用进行了计算机研究。根据所选具有活性COX-1中心的化合物(2e,2g)结合模式的选择性指数,发现化合物可以通过前列腺素生物合成途径可靠地发挥其抗炎作用,抑制COX-1而不是COX-2。1,2,4-三唑衍生物的烷基疏水相互作用对COX-1或COX-2的亲和力和选择性变化的影响也已得到证实。因此,1,2,4的衍生物是改进、进一步研究和未来开发新的、更强效的抗炎药的有希望的候选者。
{"title":"Synthesis, characterization, molecular docking studies of new alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H- -1,2,4-triazole-3-thiol.","authors":"Roman Shcherbyna,&nbsp;Valerü Kalchenko,&nbsp;Sergii Kulish,&nbsp;Volodymyr Salionov,&nbsp;Liubov Morozova,&nbsp;Natalia Nedorezaniuk,&nbsp;Olha Mazur","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The main goal of this article is to present the results of the synthesis of new alkyl derivatives of 5-(2-bromo4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiol and molecular docking studies against COX-1 and COX-2. Previous studies have established a wide range of biological activity of 1,2,4-triazole derivatives. Therefore, it was essential to determine how a new series of 1,2,4-triazole derivatives would provide potential anti-inflammatory activity. To reach the goal, raw alkyl derivatives of 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole-3-thiols (2a-2i) from 5-(2-bromo-4-fluorophenyl)-4-ethyl-4H-1,2,4-triazole3-thiol (1e) were obtained. The structure of the synthesized compounds was confirmed by 1H-NMR elemental analyses. The individuality and purity of compounds were confirmed by the method of liquid chromatography-mass spectrometry. These compounds have a relatively simple synthesis scheme, which gives them an advantage in creating a potential drug, and the appearance of alkyl radicals in the molecule should positively affect pharmacokinetic indicators, stability, selectivity, and bioavailability. An in silico study was conducted for the synthesized compounds, namely molecular docking, in relation to the interaction with COX-1 and COX-2. Based on the selectivity indexes of binding modes observed for the selected compounds (2e, 2g) with active COX-1 centers, it was found that compounds can reliably exhibit their anti-inflammatory effect through the prostaglandin biosynthesis pathway, inhibiting COX-1 instead of COX-2. The effect of hydrophobic interactions of alkyl groups of 1,2,4-triazole derivatives on changes in affinity and selectivity to COX-1 or COX-2 has also been proven. Therefore, derivatives of 1,2,4 are promising candidates for improvement, further study, and future development of new, more powerful antiinflammatory drugs for therapeutic use.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 4","pages":"190-200"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entry and competition of retail pharmacies: A case study of OTC drugs sales and ownership deregulation1. 零售药店的进入与竞争:以非处方药销售与所有权放松管制为例
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.5817/csf2023-1-11
Matúš Bilka, A. P. Duarte, M. Lábaj
This study provides new empirical evidence on the changes in competition and entry decisions of pharmacies after regulatory changes. It investigates the development of the retail pharmacy market in Portugal, which underwent major regulatory changes in 2004 and 2007. Sale of OTC drugs and ownership of pharmacies were liberalized while entry restrictions related to market size and the location of new pharmacies prevailed. Our empirical strategy was based on entry models and provided indirect information on the toughness of competition and entry decisions of firms in the market. We estimated and compared the entry thresholds and their ratios before and after liberalization. Such a comparison allows to see if competition got tenser with OTC drugs deregulated. There were three main findings from the study. First, the entry thresholds decreased regardless of the number of pharmacies in the market, suggesting that room for the realization of profits is broader than it was in the past. Second, although the entry thresholds were lower in value, their increase was steeper with each incumbent in 2020, suggesting harsher price competition with new entrants. Third, the current rule of 3,500 patients per pharmacy is likely overly restrictive, pharmacies could break-even even in smaller markets.
本研究为监管变化后药店竞争与进入决策的变化提供了新的实证证据。它调查了葡萄牙零售药房市场的发展,在2004年和2007年经历了重大的监管变化。非处方药的销售和药店的所有权已经自由化,而与市场规模和新药店所在地有关的进入限制盛行。我们的实证策略基于进入模型,并提供了关于市场竞争韧性和企业进入决策的间接信息。我们估计并比较了开放前后的准入门槛及其比率。这样的对比可以让我们看到,非处方药管制放松后,竞争是否变得更加紧张。这项研究有三个主要发现。首先,不管市场上有多少家药店,进入门槛都降低了,这表明实现利润的空间比过去更大。其次,尽管进入门槛的价值较低,但2020年每家老牌企业的门槛增幅更大,这表明与新进入者的价格竞争更激烈。第三,目前每家药房3500名患者的规定可能过于严格,药店即使在较小的市场也可能实现收支平衡。
{"title":"Entry and competition of retail pharmacies: A case study of OTC drugs sales and ownership deregulation1.","authors":"Matúš Bilka, A. P. Duarte, M. Lábaj","doi":"10.5817/csf2023-1-11","DOIUrl":"https://doi.org/10.5817/csf2023-1-11","url":null,"abstract":"This study provides new empirical evidence on the changes in competition and entry decisions of pharmacies after regulatory changes. It investigates the development of the retail pharmacy market in Portugal, which underwent major regulatory changes in 2004 and 2007. Sale of OTC drugs and ownership of pharmacies were liberalized while entry restrictions related to market size and the location of new pharmacies prevailed. Our empirical strategy was based on entry models and provided indirect information on the toughness of competition and entry decisions of firms in the market. We estimated and compared the entry thresholds and their ratios before and after liberalization. Such a comparison allows to see if competition got tenser with OTC drugs deregulated. There were three main findings from the study. First, the entry thresholds decreased regardless of the number of pharmacies in the market, suggesting that room for the realization of profits is broader than it was in the past. Second, although the entry thresholds were lower in value, their increase was steeper with each incumbent in 2020, suggesting harsher price competition with new entrants. Third, the current rule of 3,500 patients per pharmacy is likely overly restrictive, pharmacies could break-even even in smaller markets.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 1 1","pages":"11-20"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71344677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entry and competition of retail pharmacies: A case study of OTC drugs sales and ownership deregulation1. 零售药店的进入与竞争:以非处方药销售与所有权放松管制为例
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Matúš Bilka, António Portugal Duarte, Martin Lábaj

This study provides new empirical evidence on the changes in competition and entry decisions of pharmacies after regulatory changes. It investigates the development of the retail pharmacy market in Portugal, which underwent major regulatory changes in 2004 and 2007. Sale of OTC drugs and ownership of pharmacies were liberalized while entry restrictions related to market size and the location of new pharmacies prevailed. Our empirical strategy was based on entry models and provided indirect information on the toughness of competition and entry decisions of firms in the market. We estimated and compared the entry thresholds and their ratios before and after liberalization. Such a comparison allows to see if competition got tenser with OTC drugs deregulated. There were three main findings from the study. First, the entry thresholds decreased regardless of the number of pharmacies in the market, suggesting that room for the realization of profits is broader than it was in the past. Second, although the entry thresholds were lower in value, their increase was steeper with each incumbent in 2020, suggesting harsher price competition with new entrants. Third, the current rule of 3,500 patients per pharmacy is likely overly restrictive, pharmacies could break-even even in smaller markets.

本研究为监管变化后药店竞争与进入决策的变化提供了新的实证证据。它调查了葡萄牙零售药房市场的发展,在2004年和2007年经历了重大的监管变化。非处方药的销售和药店的所有权已经自由化,而与市场规模和新药店所在地有关的进入限制盛行。我们的实证策略基于进入模型,并提供了关于市场竞争韧性和企业进入决策的间接信息。我们估计并比较了开放前后的准入门槛及其比率。这样的对比可以让我们看到,非处方药管制放松后,竞争是否变得更加紧张。这项研究有三个主要发现。首先,不管市场上有多少家药店,进入门槛都降低了,这表明实现利润的空间比过去更大。其次,尽管进入门槛的价值较低,但2020年每家老牌企业的门槛增幅更大,这表明与新进入者的价格竞争更激烈。第三,目前每家药房3500名患者的规定可能过于严格,药店即使在较小的市场也可能实现收支平衡。
{"title":"Entry and competition of retail pharmacies: A case study of OTC drugs sales and ownership deregulation1.","authors":"Matúš Bilka,&nbsp;António Portugal Duarte,&nbsp;Martin Lábaj","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study provides new empirical evidence on the changes in competition and entry decisions of pharmacies after regulatory changes. It investigates the development of the retail pharmacy market in Portugal, which underwent major regulatory changes in 2004 and 2007. Sale of OTC drugs and ownership of pharmacies were liberalized while entry restrictions related to market size and the location of new pharmacies prevailed. Our empirical strategy was based on entry models and provided indirect information on the toughness of competition and entry decisions of firms in the market. We estimated and compared the entry thresholds and their ratios before and after liberalization. Such a comparison allows to see if competition got tenser with OTC drugs deregulated. There were three main findings from the study. First, the entry thresholds decreased regardless of the number of pharmacies in the market, suggesting that room for the realization of profits is broader than it was in the past. Second, although the entry thresholds were lower in value, their increase was steeper with each incumbent in 2020, suggesting harsher price competition with new entrants. Third, the current rule of 3,500 patients per pharmacy is likely overly restrictive, pharmacies could break-even even in smaller markets.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 1","pages":"11-20"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10823793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A study of hypoglycemic activity of acids and salts containing 1,2,4-triazole. 含有1,2,4-三唑的酸和盐的降糖活性研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Dmytro Dovbnia, Yuliia Frolova, Andrii Kaplaushenko

This article presents the study results of the hypoglycemic properties among 1,2,4-triazole derivatives synthesized at the Department of Physical and Colloidal Chemistry of the Zaporizhzhia State Medical University. Today, many people have a sedentary way of life, also most of their diet contains products that they frequently use, which increase the level of glucose in the blood, which can provoke the development of serious diseases. Therefore, to date, the creation of drugs that exhibit hypoglycemic activity and have a low level of toxicity remains an urgent task for medicine and pharmacy. In the first stage of our research, acute toxicity prediction was performed. The hypoglycemic activity of the synthesized compounds was assessed by performing an intraperitoneal glucose tolerance test (IPGTT) with a change in the blood glucose concentration of the animal after its single intraperitoneal administration in the form of a 40% solution at a dose of 2 g/kg of rat body weight. Thirty-eight compounds of the different classes were studied for hypoglycemic activity. Zinc (II) 2-{5-[(3,4-methoxyphenyl)-3H-1,2,4-triazole-3-yl]thio} acetate (3.18) showed the highest efficiency in terms of the ability to lower blood glucose levels, namely, by 27.3% (approximately 1.3 times).

本文介绍了在中国国立医科大学物理与胶体化学系合成的1,2,4-三唑类衍生物的降糖性能的研究结果。如今,许多人都有久坐不动的生活方式,他们的饮食中也大多含有他们经常使用的产品,这些产品会增加血液中的葡萄糖水平,从而引发严重疾病的发展。因此,迄今为止,创造具有低血糖活性和低毒性的药物仍然是医学和药学的紧迫任务。在我们研究的第一阶段,进行了急性毒性预测。通过进行腹腔葡萄糖耐量试验(IPGTT)来评估合成化合物的降糖活性,以40%的溶液形式以2 g/kg大鼠体重的剂量单次腹腔给药后动物血糖浓度的变化。研究了38种不同种类的化合物的降糖活性。锌(II) 2-{5-[(3,4-甲氧基苯基)- 3h -1,2,4-三唑-3-基]硫代乙酸酯(3.18)在降低血糖水平方面表现出最高的效率,即27.3%(约1.3倍)。
{"title":"A study of hypoglycemic activity of acids and salts containing 1,2,4-triazole.","authors":"Dmytro Dovbnia,&nbsp;Yuliia Frolova,&nbsp;Andrii Kaplaushenko","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article presents the study results of the hypoglycemic properties among 1,2,4-triazole derivatives synthesized at the Department of Physical and Colloidal Chemistry of the Zaporizhzhia State Medical University. Today, many people have a sedentary way of life, also most of their diet contains products that they frequently use, which increase the level of glucose in the blood, which can provoke the development of serious diseases. Therefore, to date, the creation of drugs that exhibit hypoglycemic activity and have a low level of toxicity remains an urgent task for medicine and pharmacy. In the first stage of our research, acute toxicity prediction was performed. The hypoglycemic activity of the synthesized compounds was assessed by performing an intraperitoneal glucose tolerance test (IPGTT) with a change in the blood glucose concentration of the animal after its single intraperitoneal administration in the form of a 40% solution at a dose of 2 g/kg of rat body weight. Thirty-eight compounds of the different classes were studied for hypoglycemic activity. Zinc (II) 2-{5-[(3,4-methoxyphenyl)-3H-1,2,4-triazole-3-yl]thio} acetate (3.18) showed the highest efficiency in terms of the ability to lower blood glucose levels, namely, by 27.3% (approximately 1.3 times).</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 3","pages":"113-124"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diazotization titrations in pharmacopoeial quality control of medicines and proposals for their revision in the European Pharmacopoeia. 药典药品质量控制中的重氮滴定法及其在《欧洲药典》中的修订建议。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Jan Šubert, Jozef Kolář, Jozef Čižmárik

Based on the data in the Ph. Eur., some other newer pharmacopoeias and published experimental papers propose to revise the text of Ph. Eur. 2.5.8. First, it is necessary to specify which of the electrometric methods should be used to indicate the endpoint of diazotization titrations in Ph. Eur. (preferable potentiometry with a platinum indicating electrode). The amount of potassium bromide in the titration solution may be reduced to 1 g, the cooling of the solution before titration may be omitted from the framework procedure, and it may be specified in individual monographs if necessary to obtain accurate and correct results for some medicines. Diazotization titration can be performed in Ph. Eur. and can also be used to determine the content of some other medicines.

根据欧洲药典中的数据,其他一些较新的药典和已发表的实验论文建议对欧洲药典2.5.8的文本进行修订。首先,有必要规定应使用哪种电位测量方法来指示欧洲药典中重氮化滴定的终点(最好使用铂指示电极进行电位测量)。滴定溶液中溴化钾的量可以减少到1g,滴定前溶液的冷却可以从框架程序中省略,必要时可以在单独的专著中进行规定,以获得某些药物的准确和正确的结果。重氮滴定法可以在欧洲药典中进行,也可以用于测定其他一些药物的含量。
{"title":"Diazotization titrations in pharmacopoeial quality control of medicines and proposals for their revision in the European Pharmacopoeia.","authors":"Jan Šubert,&nbsp;Jozef Kolář,&nbsp;Jozef Čižmárik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Based on the data in the Ph. Eur., some other newer pharmacopoeias and published experimental papers propose to revise the text of Ph. Eur. 2.5.8. First, it is necessary to specify which of the electrometric methods should be used to indicate the endpoint of diazotization titrations in Ph. Eur. (preferable potentiometry with a platinum indicating electrode). The amount of potassium bromide in the titration solution may be reduced to 1 g, the cooling of the solution before titration may be omitted from the framework procedure, and it may be specified in individual monographs if necessary to obtain accurate and correct results for some medicines. Diazotization titration can be performed in Ph. Eur. and can also be used to determine the content of some other medicines.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 4","pages":"165-171"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41147435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the anti-inflammatory properties of a thick extract of Tribulus terrestris L. 雷公藤粗提物抗炎作用的研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01
Saida Yunusova, Yaroslav Rozhkovskyi, Bohdan Prystupa, Svitlana Bohatu

The most promising direction in the treatment of chronic prostatitis is the use of medicinal plants and preparations based on them, which contain natural compounds with a broad spectrum of pharmacological activity: anti-inflammatory, antimicrobial, reparative, immunomodulatory, hormone-regulating, antisclerotic, etc., and which can provide a complex therapeutic effect on the course of chronic prostatitis. A promising raw material in this direction is Tribulus terrestris L., a herbal preparation traditionally used to treat erectile dysfunction and atherosclerosis. This experimental work aims to study the anti-inflammatory activity of a thick extract of the Tribulus terrestris grass (freed from fruits) on the models of carrageenan and zymosan inflammation in rats. In the models of carrageenan and zymosan edema in rats, a thick extract of Tribulus terrestris L. in doses from 50 mg/kg to 200 mg/kg shows anti-inflammatory activity, the efficacy of which in the dose range of 150-200 mg/g in the initial stages of carrageenan inflammation is not inferior to sodium diclofenac at a dose of 8.0 mg/kg, and in the initial stages of zymosan inflammation, respectively, before the reference drug corvitin at a dose of 10 mg/kg. It indicates the anticyclogenase and antilipoxygenase properties of this thick extract.

治疗慢性前列腺炎最有前景的方向是使用药用植物及其制剂,这些植物和制剂含有具有广泛药理活性的天然化合物:抗炎、抗菌、修复、免疫调节、激素调节、抗硬化等。,并且可以对慢性前列腺炎的过程提供复杂的治疗效果。在这个方向上,一种很有前途的原料是Tributus terrestris L.,一种传统上用于治疗勃起功能障碍和动脉粥样硬化的草药制剂。本实验旨在研究一种从果实中提取的刺五加粗提取物对大鼠卡拉胶和酵母多糖炎症模型的抗炎活性。在大鼠角叉菜胶和酵母多糖水肿模型中,50 mg/kg至200 mg/kg剂量的雷公藤粗提取物显示出抗炎活性,其在角叉菜菜胶炎症初始阶段150至200 mg/kg的剂量范围内的疗效分别不劣于8.0 mg/kg剂量的双氯芬酸钠和在酵母多糖炎症初始阶段,在10mg/kg剂量的参考药物corvitin之前。这表明这种厚提取物具有抗环氧化酶和抗脂氧合酶的特性。
{"title":"Study of the anti-inflammatory properties of a thick extract of Tribulus terrestris L.","authors":"Saida Yunusova,&nbsp;Yaroslav Rozhkovskyi,&nbsp;Bohdan Prystupa,&nbsp;Svitlana Bohatu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The most promising direction in the treatment of chronic prostatitis is the use of medicinal plants and preparations based on them, which contain natural compounds with a broad spectrum of pharmacological activity: anti-inflammatory, antimicrobial, reparative, immunomodulatory, hormone-regulating, antisclerotic, etc., and which can provide a complex therapeutic effect on the course of chronic prostatitis. A promising raw material in this direction is Tribulus terrestris L., a herbal preparation traditionally used to treat erectile dysfunction and atherosclerosis. This experimental work aims to study the anti-inflammatory activity of a thick extract of the Tribulus terrestris grass (freed from fruits) on the models of carrageenan and zymosan inflammation in rats. In the models of carrageenan and zymosan edema in rats, a thick extract of Tribulus terrestris L. in doses from 50 mg/kg to 200 mg/kg shows anti-inflammatory activity, the efficacy of which in the dose range of 150-200 mg/g in the initial stages of carrageenan inflammation is not inferior to sodium diclofenac at a dose of 8.0 mg/kg, and in the initial stages of zymosan inflammation, respectively, before the reference drug corvitin at a dose of 10 mg/kg. It indicates the anticyclogenase and antilipoxygenase properties of this thick extract.</p>","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"72 4","pages":"184-189"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ceska a Slovenska Farmacie
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1